Fortitude Family Office’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.56K Hold
53
– – ﹤0.01% 1356
2026
Q2
$8.31K Hold
53
– – ﹤0.01% 853
2026
Q1
$8.1K Hold
53
– – ﹤0.01% 726
2025
Q4
$7.31K Hold
53
– – ﹤0.01% 687
2025
Q3
$6.8K Hold
53
– – ﹤0.01% 701
2025
Q2
$6.41K Hold
53
– – ﹤0.01% 697
2025
Q1
$5.91K Sell
53
-139
-72% -$14.8K ﹤0.01% 683
2024
Q4
$18.7K Sell
192
-128
-40% -$13.7K 0.01% 468
2024
Q3
$36.8K Buy
320
+267
+504% +$30.3K 0.01% 295
2024
Q2
$5.64K Hold
53
– – ﹤0.01% 549
2024
Q1
$5.13K Hold
53
– – ﹤0.01% 597
2023
Q4
$5.35K Buy
+53
New +$5.12K ﹤0.01% 595

Other funds holding NVS

Fortitude Family Office's NVS Position: Q3 2026 in Review

Fortitude Family Office held its Novartis (NVS) position steady in Q3 2026 at 53 shares worth $7.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1356.

Fortitude Family Office first reported a position in NVS in Q4 2023 and has held it in 12 quarters since. The position peaked at $36.8K in Q3 2024. 223 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Fortitude Family Office held 53 shares of Novartis worth $7.56K as of Q3 2026.
  • Fortitude Family Office left its Novartis share count unchanged in Q3 2026.
  • Novartis made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1356 holding.
  • Fortitude Family Office first reported a position in Novartis in Q4 2023 and has held it in 12 quarters since.
  • Fortitude Family Office's Novartis position peaked at $36.8K in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.